Literature DB >> 369375

Accumulation of norethindrone and individual metabolites in human plasma during short- and long-term administration of a contraceptive dosage.

W E Braselton, T J Lin, J O Ellegood, T M Mills, V B Mahesh.   

Abstract

Blood levels of free, sulfate, and glucuronide conjugates of norethindrone (NE) and its ring A reduced metabolites 17alpha-ethynyl-5beta-estrane-3alpha, 17beta-diol and 17alpha-ethynyl-5alpha-estrane-3alpha, 17beta-diol were measured in a female volunteer who received six consecutive daily doses of 2.5 mg. of NE and in four female volunteers undergoing chronic treatment with Orthonovum 2 mg. (2 mg. of NE and 0.1 mg. of mestranol [ME]). The blood levels were quantified by gas chromatograph-mass spectrometry. During treatment for 6 days with 2.5 mg. of NE daily, the 3 hour blood levels of NE and the ring A reduced metabolites increased in a stepwise fashion. During long-term treatment the concentrations of NE, NE sulfate, and the conjugates of the ring A reduced metabolites were seen to build up to a peak at approximately the midpoint of the treatment phase of each cycle, and drop to near baseline during the time when no drug was administered. Individuals varied as to their tendency to accumulate the drug and metabolites, and as to the relative proportion of metabolites formed.

Entities:  

Keywords:  Age Factors; Anthropometry; Biology; Body Weight; Child Development; Clinical Research; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Demographic Factors; Examinations And Diagnoses; Family Planning; Growth; Human Volunteers; Laboratory Examinations And Diagnoses; Laboratory Procedures; Mestranol--administraction and dosage; Norethindrone--administraction and dosage; Norethindrone--analysis; Oral Contraceptives; Physiology; Population; Population Characteristics; Research Methodology; Women

Mesh:

Substances:

Year:  1979        PMID: 369375     DOI: 10.1016/0002-9378(79)90467-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.

Authors:  R Poulin; D Baker; D Poirier; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

2.  Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.

Authors:  Yi Jin; Ling Duan; Mo Chen; Trevor M Penning; Helenius J Kloosterboer
Journal:  J Steroid Biochem Mol Biol       Date:  2011-12-28       Impact factor: 4.292

Review 3.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

4.  Radioimmunological determination of levonorgestrel and ethinylestradiol.

Authors:  Q G Li; B Nieuweboer
Journal:  J Tongji Med Univ       Date:  1989

5.  Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.

Authors:  A M Pasapera; R Gutiérrez-Sagal; R García-Becerra; A Ulloa-Aguirre; J F Savouret
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

Review 6.  Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective.

Authors:  Virendra B Mahesh
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.